pp-090 Injection
Dossier type
CTD
Dossier status
Under development
Country of origin
Japan
Comments
Indication: Ankylosing spondylitis requiring IL-17A pathway suppression.
Clinical stage: Phase 2 (Japan).
Modality: Antibody-inducing peptide vaccine.
Mechanism / Target: Generates IL-17A-neutralizing antibodies via AJP001-mediated T-cell help and B-cell activation.
Route / form: Subcutaneous injection.
Differentiation: Potential for long-acting IL-17A control with fewer injections and lower cost relative to monoclonal antibody therapies.
Manufacturer #38644
A clinical-stage biotechnology firm advancing functional and antibody-inducing peptide medicines to address immune, skin and inflammatory conditions with aims to reduce patient burden versus traditional biologics. It builds on academic peptide technology with global R&D and strategic collaborations. The organization leverages peptide platforms for next-generation vaccines and therapeutic candidates.